IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 6.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 142,630 shares of the company's stock after selling 9,276 shares during the quarter. California Public Employees Retirement System owned 0.17% of IDEXX Laboratories worth $58,969,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IDXX. Insight Wealth Strategies LLC increased its holdings in IDEXX Laboratories by 230.5% in the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock valued at $4,174,000 after buying an additional 7,041 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of IDEXX Laboratories by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company's stock worth $1,138,732,000 after acquiring an additional 40,349 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in IDEXX Laboratories in the 3rd quarter valued at approximately $1,263,000. Sax Wealth Advisors LLC raised its holdings in IDEXX Laboratories by 76.3% during the fourth quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company's stock worth $590,000 after purchasing an additional 617 shares during the last quarter. Finally, Hantz Financial Services Inc. boosted its position in IDEXX Laboratories by 11.5% during the fourth quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company's stock worth $3,199,000 after purchasing an additional 800 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several research reports. Morgan Stanley cut their price target on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Barclays lifted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Friday. Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Finally, Bank of America increased their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Trading Down 4.1 %

Shares of IDXX stock traded down $17.03 during mid-day trading on Friday, hitting $393.73. 1,635,645 shares of the company's stock were exchanged, compared to its average volume of 592,932. The stock has a market cap of $31.91 billion, a price-to-earnings ratio of 36.90, a PEG ratio of 3.41 and a beta of 1.50. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a fifty-two week low of $393.50 and a fifty-two week high of $548.88. The stock has a 50-day simple moving average of $435.55 and a two-hundred day simple moving average of $439.31.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares of the company's stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.